Valemetostat Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma: Insights from a First-in-Human Phase 1 Study

Study Background and Research Question

Epigenetic dysregulation, particularly trimethylation of histone H3 at lysine 27 (H3K27me3), is implicated in the pathogenesis of non-Hodgkin lymphoma (NHL). The enzymatic activity responsible for this mark is primarily mediated by the histone methyltransferases EZH2 and EZH1, both components of Polycomb Repressive Complex 2 (PRC2). Mutations in EZH2, especially at residues such as Y641, A677, and A687, are recurrent in several lymphoma subtypes and correlate with aggressive disease and poor response to conventional therapies. As few targeted treatments exist for relapsed or refractory NHL, the clinical evaluation of agents that modulate these epigenetic regulators is a high priority. The referenced phase 1 study (Maruyama et al., 2024) was designed to assess the safety, pharmacokinetics, and preliminary efficacy of Valemetostat (DS-3201) in this challenging patient population.

Key Innovation from the Reference Study

Valemetostat (DS-3201) is a first-in-class, orally available, selective dual inhibitor of EZH1 and EZH2, with pronounced selectivity and potency against both wild-type and mutant EZH2. Unlike earlier EZH2 inhibitors, Valemetostat inhibits both EZH2 and EZH1, potentially overcoming compensatory mechanisms that limit the efficacy of single-target agents. This dual activity is especially relevant in the context of relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma, where EZH2 mutations contribute to disease persistence and resistance. The phase 1 study represents the first comprehensive clinical assessment of this dual-inhibition strategy in NHL, providing foundational data for future epigenetic cancer therapy approaches.

Methods and Experimental Design Insights

The multicentre, open-label, single-arm study consisted of dose-escalation and dose-expansion phases, enrolling adult patients with relapsed or refractory non-Hodgkin lymphoma across 19 hospitals in Japan and the USA. Key eligibility criteria included a confirmed diagnosis of relapsed/refractory NHL and an ECOG performance status of 0–1. In the dose-escalation phase, Valemetostat was administered orally at 150, 200, 250, or 300 mg per day, following continuous 28-day cycles. The dose-expansion cohort received 200 mg per day. The primary endpoints encompassed safety, pharmacokinetics, and determination of the recommended phase 2 dose (RP2D); secondary endpoints included maximum tolerated dose (MTD) and antitumor efficacy, as assessed by standardized lymphoma response criteria. All patients received Valemetostat until disease progression or unacceptable toxicity.

Protocol Parameters

• Dosing schedule (study protocol): Oral administration of Valemetostat at 150–300 mg per day, continuous 28-day cycles, with most patients in expansion receiving 200 mg per day.
• Patient selection: Adults (≥18 USA, ≥20 Japan) with relapsed/refractory NHL, ECOG 0–1, measurable lesions per IWG 2007/modified 2009 criteria.
• Response assessment: Based on International Working Group (IWG) 2007 revised criteria for malignant lymphoma and modified 2009 criteria for adult T-cell leukemia/lymphoma.
• Adverse event monitoring: Continuous assessment using CTCAE grading, including hematologic and non-hematologic events.
• Duration: Median follow-up of 7.4 months (IQR 3.4–17.6).

Core Findings and Why They Matter

The study enrolled 90 patients: 63% with peripheral T-cell lymphoma, 16% with adult T-cell leukemia/lymphoma, and 21% with B-cell NHL. Among the 88 patients evaluable for efficacy, the overall response rate (ORR) was 54.5% (95% CI 43.6–65.2), with responses observed across multiple NHL subtypes. Importantly, the maximum tolerated dose was not reached, and the recommended phase 2 dose was established at 200 mg per day. The safety profile was considered acceptable, with the most frequent treatment-emergent adverse events being thrombocytopenia (58%), dysgeusia (50%), and anemia (42%). Grade 3–4 adverse events were mainly hematologic, including neutropenia (23%), thrombocytopenia (20%), and lymphopenia (19%). There were no treatment-related deaths, and the most common serious adverse event was Pneumocystis jirovecii pneumonia (4%).

These results demonstrate that Valemetostat achieves clinically meaningful responses in a heavily pretreated population with manageable toxicity, supporting its further development as an epigenetic therapy for relapsed/refractory NHL. The robust activity in both EZH2 wild-type and mutant disease highlights the value of dual EZH1/2 inhibition, especially given the heterogeneity of underlying mutations in this patient group (Maruyama et al., 2024).

Comparison with Existing Internal Articles

Several internal resources provide additional context for implementing Valemetostat in research workflows. For example, the guide "Valemetostat (DS-3201): Precision Workflows for Lymphoma Research" offers detailed protocols and troubleshooting insights for translational studies. Similarly, "Valemetostat (DS-3201): Precision EZH2 Inhibition in Lymphoma" emphasizes the compound’s nanomolar potency and reproducibility in vitro, especially in models of relapsed/refractory follicular lymphoma with EZH2 mutations. Workflow-driven guidance in "Workflow-Driven Lymphoma Research" further supports optimized assay design, while "Reliable EZH2 Inhibition for Epigenetic Assays" addresses issues such as selectivity and cytotoxicity assessment. Collectively, these resources align with the clinical data, reinforcing Valemetostat’s utility for high-fidelity epigenetic interrogation in lymphoma research.

Limitations and Transferability

While the phase 1 trial establishes the safety and potential efficacy of Valemetostat in relapsed/refractory NHL, several limitations must be considered. The study was open-label and single-arm, lacking a direct comparator, which may introduce response assessment biases. The patient cohort was heterogeneous, including multiple NHL subtypes with distinct molecular drivers, making subtype-specific efficacy interpretation challenging. Pharmacokinetic variability was observed, with overlapping exposure across the 150–250 mg dose range, suggesting interpatient differences in drug metabolism or absorption. Additionally, the follow-up duration (median 7.4 months) limits long-term assessment of durability and late-onset toxicities. These factors should be addressed in ongoing or planned phase 2/3 studies to confirm and expand upon these preliminary results.

Research Support Resources

For investigators seeking to replicate or extend these findings, Valemetostat (SKU BA4816) is available for research use as a dual EZH1/2 inhibitor with validated potency and selectivity. Protocols and product details, including solubility, storage, and recommended working concentrations, can be found on the APExBIO product page. This resource can be integrated into preclinical workflows, cell-based assays, and translational lymphoma research, facilitating the exploration of EZH2 and EZH1 inhibition in diverse experimental models. Internal guides cited above provide additional workflow tips and troubleshooting strategies for maximizing reproducibility and data quality.